Viral safety of B-domain deleted recombinant factor VIII
- 30 April 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 32-39
- https://doi.org/10.1016/s0037-1963(01)90106-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 1996
- Virus safety considerations for recombinant factor VIII (rFVIII, Kogenate)Haemophilia, 1995
- Recombinate: viral safety and final product manufacturing testing and specificationsAnnals of Hematology, 1994
- Cell culture and purification process — purity and safety testingAnnals of Hematology, 1994
- Design and operation of a recombinant mammalian cell manufacturing process for rFVIIIAnnals of Hematology, 1994
- Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrateJournal of Medical Virology, 1994
- Clinical Evaluation of Viral Safety of Coagulation Factor VIII and IX ConcentratesVox Sanguinis, 1993
- Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 1992
- Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 1990
- Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinationsTransfusion, 1985